Medscape November 4, 2024
Miriam E. Tucker

The US Food and Drug Administration (FDA) has cleared the Abbott Libre 2 and 3 continuous glucose monitoring (CGM) sensors for use during most imaging procedures, including MRI under certain specifications.

“Abbott rigorously tested its FreeStyle Libre 2 and 3 systems sensors to ensure they remain effective after radiologic procedures. This testing led the FDA to clear the removal of the contraindication requirement, with no changes made to the sensor,” the company said in a statement.

The sensors may also now be worn during CT or x-ray procedures. Previously, they were contraindicated for use during MRI, CT, and high-frequency electrical heat (diathermy) treatment due to concern that the exposure could potentially damage the sensor and lead to incorrect readings. Those...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, Provider, Radiology, Technology, Wearables
How Digital Health Tools, AI, and Wearables are Transforming Care and Self-Management
ŌURA Promises Relentless Innovation As It Hits New Oura Ring Milestone
FDA Clears Withings’ New Blood Pressure Monitor That Allows Providers to Communicate Directly with Patients
B2B Wearables: A New Tool for Businesses to Promote Workplace Wellness
Q&A: Continuous health monitoring with wearables

Share This Article